SEC	Form	4
-----	------	---

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287
	Estimated average burde	n
	hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

-			or Section 30(n) of the investment Company Act of 1940				
1. Name and Address of Reporting Person* ROE ROBERT L (Last) (First) (Middle) C/O CORCEPT THERAPEUTICS		(Middle)	2. Issuer Name and Ticker or Trading Symbol <u>CORCEPT THERAPEUTICS INC</u> [CORT] 3. Date of Earliest Transaction (Month/Day/Year) 01/30/2013		lationship of Reporting Person(s) to Issuer k all applicable) Director 10% Owner Officer (give title Other (specify below) President and Secretary		
149 COMMONV	VEALTH DRIVE			<u> </u>			
(Street) MENLO PARK (City)	reet) IENLO PARK CA 94025		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi Line) X	idual or Joint/Group Filing Form filed by One Repo Form filed by More than Person	rting Person	
	Ta	able I - Non-Deriv	ative Securities Acquired, Disposed of, or Benefi	cially C)wned		

 2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (ction	4. Securities Acquired (Disposed Of (D) (Instr. 3			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
		Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(11311.4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Derivative I		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Stock option (right to buy)	\$2.075	01/30/2013		A		200,000		(1)	01/30/2023	Common Stock	200,000	\$0.00	200,000	D	

Explanation of Responses:

1. Exercisable with respect to 2.08334% of the total number of Option Shares on the monthly anniversary of 1/30/2013 and each month thereafter.

Remarks:

/s/ Joseph K. Belanoff, CEO of **Corcept Therapeutics**

Incorporated, attorney-in-fact ** Signature of Reporting Person

02/01/2013

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.